- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective, Multicentre
- Study aim: To analyse first-line COVID-19 combination regimens for virological and clinical outcomes and safety in a large cohort of immunocompromised patients
- Number of participants enrolled: 144
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults
- Elderly
- Fragile population
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
External Links
Other information
Funders:
- Projekt DEAL
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to